✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PainResearchTHCCBD Why This Matters Clinicians treating patients with myofascial pain now have emerging evidence that...
Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchNeurologyAgingSafety Why This Matters Clinicians can use this evidence to reassure older patients that lifetime...
Daily Digest 2026-03-05
✦ New Top items from the CED news pipeline. (82) Scientists are raising new concerns about marijuana use in teens – KPBSResearch continues to build a concerning picture around adolescent cannabis use...
Regulatory Digest 2026-03-05
✦ New Regulatory updates (higher clinical relevance) (100) [regulations.gov] Schedules of Controlled Substances: Rescheduling of Marijuana (85) [regulations.gov] Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368 (85) [regulations.gov] Exempt Chemical Preparations May 2024 (2024-10465) –...
Daily Digest: Last 24 Hours: Brain Aging, Driving Safety, and the Global Fight for Patient Access — March 05, 2026
Last 24 Hours March 05, 2026 — 57 articles reviewed This cycle’s coverage centered on reassuring longitudinal data about cannabis and cognitive aging in older adults, mounting evidence that THC blood levels...
In the Mix: 9 More Articles — March 05, 2026
9 cannabis articles reviewed and scored below the CED clinical relevance threshold in the March 05, 2026 feed update. Organized by topic with summaries and source links.
Oklahoma Seeks to Backtrack on Medical Marijuana as Pitfalls Multiply
WHY IT MATTERS: Oklahoma patients currently relying on medical cannabis for chronic conditions should monitor proposed legislative changes closely, as restrictions or program shutdowns could interrupt ongoing treatment without any transition plan in place. CLINICAL OVERVIEW: Oklahoma built one of the most permissive medical cannabis frameworks in the country, and the rapid expansion exposed real regulatory gaps including oversaturation of dispensaries, diversion concerns, and inconsistent product oversight. The push to roll back the program reflects a broader tension between voter-approved access and the infrastructure required to sustain a safe, functional medical system.
Pres. Trump’s Marijuana Executive Mandate Accelerates MMJ International Holdings … – Newswire
WHY IT MATTERS: Patients seeking medical cannabis products manufactured to pharmaceutical standards may find broader availability and greater product consistency if U.S. federal policy changes open legitimate pathways for GMP-certified producers to scale and export. CLINICAL OVERVIEW: Federal policy shifts around cannabis scheduling and executive action have historically created both opportunity and uncertainty for companies operating at the intersection of pharmaceutical-grade cannabis and international markets. When regulatory frameworks begin to clarify, manufacturers with established GMP infrastructure and clinical trial experience are better positioned to meet the evidentiary standards that pharmaceutical buyers and foreign health authorities require.
Cannabis industry launches organization to further US policy changes with members from …
WHY IT MATTERS: The policies shaped by this kind of industry coalition could directly affect what medical cannabis products are available to patients, how they are labeled, and whether insurance or federal programs ever cover them. CLINICAL OVERVIEW: The formation of a cross-border cannabis industry coalition comes at a pivotal moment when federal rescheduling discussions in the United States are creating real regulatory uncertainty for both patients and producers. Industry-led organizations of this kind can play a meaningful role in shaping the evidentiary standards and policy frameworks that ultimately determine how patients access medical cannabis, what labeling and dosing information is required, and how physicians are permitted to recommend it.
The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators
WHY IT MATTERS: Patients seeking cannabinoid-based treatments may find that the medicines with the strongest clinical evidence available elsewhere in the world remain inaccessible in the U.S. not because of safety concerns, but because of who is permitted to conduct the research in the first place. CLINICAL OVERVIEW: The United States maintains a uniquely fragmented regulatory environment for cannabis research, where federal scheduling under the Controlled Substances Act creates structural barriers that foreign operators and even domestic companies struggle to navigate when developing cannabinoid-based medicines. Unlike pharmaceuticals that can be studied and approved through relatively standardized international pathways, cannabis research in the U.S.